Complement activation by cholesterol crystals triggers a subsequent cytokine response

Molecular Immunology

Volumn 84, Issue , 2017, Pages 43-50

  Niyonzima, Nathalie ^a,b   Halvorsen, Bente ^c,d   Sporsheim, Bjørnar ^a   Garred, Peter ^e   Aukrust, Pål ^c,d   Mollnes, Tom Eirik ^a,c,d,f,g   Espevik, Terje ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF TROMSØ   (Norway)

^g NORDLAND HOSPITAL   (Norway)

Author keywords

Atherosclerosis; Cholesterol crystals; Complement; Inflammasome; Interleukin 1beta

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHOLESTEROL; CHOLESTEROL CRYSTAL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; CRYOPYRIN; CRYSTALLIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; GENE EXPRESSION; INFLAMMATION; INNATE IMMUNITY; PATHOPHYSIOLOGY; PHAGOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CAROTID ARTERY OBSTRUCTION; HUMAN; IMMUNOLOGY;

ANIMALS; ATHEROSCLEROSIS; CAROTID STENOSIS; CHOLESTEROL; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; INFLAMMATION;

EID: 85008661006     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2016.09.019     Document Type: Article

References (74)

1. An, L.L., Mehta, P., Xu, L., Turman, S., Reimer, T., Naiman, B., Connor, J., Sanjuan, M., Kolbeck, R., Fung, M., Complement C5a potentiates uric acid crystal-induced IL-1beta production. Eur. J. Immunol. 44 (2014), 3669–3679.
2. Arbore, G., West, E.E., Spolski, R., Robertson, A.A., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T.M., Yu, Z.X., O'Neill, L.A., Coll, R.C., Sher, A., Leonard, W.J., Kohl, J., Monk, P., Cooper, M.A., Arno, M., Afzali, B., Lachmann, H.J., Cope, A.P., Mayer-Barber, K.D., Kemper, C., T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science, 352, 2016, aad1210.
3. Atger, V.M., de la Llera Moya, M., Stoudt, G.W., Rodrigueza, W.V., Phillips, M.C., Rothblat, G.H., Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J. Clin. Invest. 99 (1997), 773–780.
4. Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M., Fogelman, A.M., Antiinflammatory properties of HDL. Circ. Res. 95 (2004), 764–772.
5. Bauernfeind, F.G., Horvath, G., Stutz, A., Alnemri, E.S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B.G., Fitzgerald, K.A., Hornung, V., Latz, E., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183 (2009), 787–791.
6. Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Nunez, G., Hornung, V., Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187 (2011), 613–617.
7. Bours, M.J., Swennen, E.L., Di Virgilio, F., Cronstein, B.N., Dagnelie, P.C., Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112 (2006), 358–404.
8. Busso, N., So, A., Mechanisms of inflammation in gout. Arthritis Res. Ther., 12, 2010, 206.
9. Chen, C.J., Kono, H., Golenbock, D., Reed, G., Akira, S., Rock, K.L., Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13 (2007), 851–856.
10. Coulthard, L.G., Woodruff, T.M., Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J. Immunol. 194 (2015), 3542–3548.
11. De Nardo, D., Labzin, L.I., Kono, H., Seki, R., Schmidt, S.V., Beyer, M., Xu, D., Zimmer, S., Lahrmann, C., Schildberg, F.A., Vogelhuber, J., Kraut, M., Ulas, T., Kerksiek, A., Krebs, W., Bode, N., Grebe, A., Fitzgerald, M.L., Hernandez, N.J., Williams, B.R., Knolle, P., Kneilling, M., Rocken, M., Lutjohann, D., Wright, S.D., Schultze, J.L., Latz, E., High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 15 (2014), 152–160.
12. Devlin, C.M., Kuriakose, G., Hirsch, E., Tabas, I., Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 6280–6285.
13. Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., Tschopp, J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008), 674–677.
14. Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., Abela, G.S., Franchi, L., Nunez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K.A., Rock, K.L., Moore, K.J., Wright, S.D., Hornung, V., Latz, E., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
15. Ea, H.K., Liote, F., Calcium pyrophosphate dihydrate and basic calcium phosphate crystal-induced arthropathies: update on pathogenesis, clinical features, and therapy. Curr. Rheumatol. Rep. 6 (2004), 221–227.
16. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S., Flavell, R.A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008), 1122–1126.
17. Eltzschig, H.K., Eckle, T., Ischemia and reperfusion–from mechanism to translation. Nat. Med. 17 (2011), 1391–1401.
18. Feig, J.E., Rong, J.X., Shamir, R., Sanson, M., Vengrenyuk, Y., Liu, J., Rayner, K., Moore, K., Garabedian, M., Fisher, E.A., HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7166–7171.
19. Franklin, B.S., Mangan, M.S., Latz, E., Crystal formation in inflammation. Annu. Rev. Immunol. 34 (2016), 173–202.
20. Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S.E., Holt, C.M., Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16 (1996), 1000–1006.
21. Garred, P., Honore, C., Ma, Y.J., Rorvig, S., Cowland, J., Borregaard, N., Hummelshoj, T., The genetics of ficolins. J. Innate Immun. 2 (2010), 3–16.
22. Gould, S., Scott, R.C., 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem. Toxicol. 43 (2005), 1451–1459.
23. Grant, R.W., Dixit, V.D., Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front. Immunol., 4, 2013, 50.
24. Gross, O., Thomas, C.J., Guarda, G., Tschopp, J., The inflammasome: an integrated view. Immunol. Rev. 243 (2011), 136–151.
25. Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., Golenbock, D.T., The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9 (2008), 857–865.
26. Hammerschmidt, D.E., Greenberg, C.S., Yamada, O., Craddock, P.R., Jacob, H.S., Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J. Lab. Clin. Med. 98 (1981), 68–77.
27. Hansen, S.W., Ohtani, K., Roy, N., Wakamiya, N., The collectins CL-L1, CL-K1 and CL-P1, and their roles in complement and innate immunity. Immunobiology, 221, 2016.
28. Hansson, G.K., Hermansson, A., The immune system in atherosclerosis. Nat. Immunol. 12 (2011), 204–212.
29. Isoda, K., Sawada, S., Ishigami, N., Matsuki, T., Miyazaki, K., Kusuhara, M., Iwakura, Y., Ohsuzu, F., Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1068–1073.
30. Janeway, C.A. Jr., Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54:Pt 1 (1989), 1–13.
31. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., Seishima, M., Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 656–660.
32. Klegeris, A., McGeer, P.L., Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem. Biophys. Res. Commun. 357 (2007), 1096–1099.
33. Kohl, J., The role of complement in danger sensing and transmission. Immunol. Res. 34 (2006), 157–176.
34. Kolev, M., Le Friec, G., Kemper, C., Complement–tapping into new sites and effector systems. Nat. Rev. Immunol. 14 (2014), 811–820.
35. Kolev, M., Dimeloe, S., Le Friec, G., Navarini, A., Arbore, G., Povoleri, G.A., Fischer, M., Belle, R., Loeliger, J., Develioglu, L., Bantug, G.R., Watson, J., Couzi, L., Afzali, B., Lavender, P., Hess, C., Kemper, C., Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42 (2015), 1033–1047.
36. Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis. Nature 473 (2011), 317–325.
37. Liszewski, M.K., Kolev, M., Le Friec, G., Leung, M., Bertram, P.G., Fara, A.F., Subias, M., Pickering, M.C., Drouet, C., Meri, S., Arstila, T.P., Pekkarinen, P.T., Ma, M., Cope, A., Reinheckel, T., Rodriguez de Cordoba, S., Afzali, B., Atkinson, J.P., Kemper, C., Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39 (2013), 1143–1157.
38. Liu, S.M., Cogny, A., Kockx, M., Dean, R.T., Gaus, K., Jessup, W., Kritharides, L., Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages. J. Lipid Res. 44 (2003), 1156–1166.
39. Matzinger, P., The danger model: a renewed sense of self. Science 296 (2002), 301–305.
40. McGeer, P.L., McGeer, E.G., Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22 (2001), 799–809.
41. Meuwissen, M., van der Wal, A.C., Niessen, H.W., Koch, K.T., de Winter, R.J., van der Loos, C.M., Rittersma, S.Z., Chamuleau, S.A., Tijssen, J.G., Becker, A.E., Piek, J.J., Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J. Clin. Pathol. 59 (2006), 196–201.
42. Mineo, C., Deguchi, H., Griffin, J.H., Shaul, P.W., Endothelial and antithrombotic actions of HDL. Circ. Res. 98 (2006), 1352–1364.
43. Mollnes, T.E., Brekke, O.L., Fung, M., Fure, H., Christiansen, D., Bergseth, G., Videm, V., Lappegard, K.T., Kohl, J., Lambris, J.D., Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002), 1869–1877.
44. Mossman, B.T., Churg, A., Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 157 (1998), 1666–1680.
45. Nakashima, Y., Raines, E.W., Plump, A.S., Breslow, J.L., Ross, R., Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 842–851.
46. Nicklin, M.J., Hughes, D.E., Barton, J.L., Ure, J.M., Duff, G.W., Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191 (2000), 303–312.
47. Niyonzima, N., Samstad, E.O., Aune, M.H., Ryan, L., Bakke, S.S., Rokstad, A.M., Wright, S.D., Damas, J.K., Mollnes, T.E., Latz, E., Espevik, T., Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J. Immunol. 195 (2015), 257–264.
48. Nuki, G., Simkin, P.A., A concise history of gout and hyperuricemia and their treatment. Arthritis Res. Ther., 8(Suppl. 1), 2006, S1.
49. Nymo, S., Niyonzima, N., Espevik, T., Mollnes, T.E., Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF. Immunobiology 219 (2014), 786–792.
50. Paramel Varghese, G., Folkersen, L., Strawbridge, R.J., Halvorsen, B., Yndestad, A., Ranheim, T., Krohg-Sorensen, K., Skjelland, M., Espevik, T., Aukrust, P., Lengquist, M., Hedin, U., Jansson, J.H., Fransen, K., Hansson, G.K., Eriksson, P., Sirsjo, A., NLRP3 inflammasome expression and activation in human atherosclerosis. J. Am. Heart Assoc., 5, 2016.
51. Pilely, K., Rosbjerg, A., Genster, N., Gal, P., Pal, G., Halvorsen, B., Holm, S., Aukrust, P., Bakke, S.S., Sporsheim, B., Nervik, I., Niyonzima, N., Bartels, E.D., Stahl, G.L., Mollnes, T.E., Espevik, T., Garred, P., Cholesterol crystals activate the lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis. J. Immunol. 196 (2016), 5064–5074.
52. Quintana, F.J., Cohen, I.R., Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J. Immunol. 175 (2005), 2777–2782.
53. Ridker, P.M., Thuren, T., Zalewski, A., Libby, P., Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am. Heart J. 162 (2011), 597–605.
54. Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., Hensen, J., Thuren, T., Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
55. Samstad, E.O., Niyonzima, N., Nymo, S., Aune, M.H., Ryan, L., Bakke, S.S., Lappegard, K.T., Brekke, O.L., Lambris, J.D., Damas, J.K., Latz, E., Mollnes, T.E., Espevik, T., Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192 (2014), 2837–2845.
56. Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002), 191–195.
57. Seifert, P.S., Kazatchkine, M.D., Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol. Immunol. 24 (1987), 1303–1308.
58. Shaw, J.A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., Mukhamedova, N., Woollard, K., Lyon, S., Sviridov, D., Dart, A.M., Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103 (2008), 1084–1091.
59. Speidl, W.S., Kastl, S.P., Huber, K., Wojta, J., Complement in atherosclerosis: friend or foe?. J. Thromb. Haemost. 9 (2011), 428–440.
60. Tabas, I., Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10 (2010), 36–46.
61. Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
62. Tardif, J.C., Gregoire, J., L'Allier, P.L., Ibrahim, R., Lesperance, J., Heinonen, T.M., Kouz, S., Berry, C., Basser, R., Lavoie, M.A., Guertin, M.C., Rodes-Cabau, J., Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007), 1675–1682.
63. Tegla, C.A., Cudrici, C., Patel, S., Trippe, R., 3rd, Rus, V., Niculescu, F., Rus, H., Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 51 (2011), 45–60.
64. Torzewski, M., Torzewski, J., Bowyer, D.E., Waltenberger, J., Fitzsimmons, C., Hombach, V., Gabbert, H.E., Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 2448–2452.
65. Vlaicu, R., Niculescu, F., Rus, H.G., Cristea, A., Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57 (1985), 163–177.
66. Vlaicu, R., Rus, H.G., Niculescu, F., Cristea, A., Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55 (1985), 35–50.
67. Vogt, W., von Zabern, I., Damerau, B., Hesse, D., Luhmann, B., Nolte, R., Mechanisms of complement activation by crystalline cholesterol. Mol. Immunol. 22 (1985), 101–106.
68. Wang, H., Wang, C., Zhao, M.H., Chen, M., Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol. 181 (2015), 518–527.
69. Warnatsch, A., Ioannou, M., Wang, Q., Papayannopoulos, V., Inflammation. neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349 (2015), 316–320.
70. Weiner, H.L., Frenkel, D., Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6 (2006), 404–416.
71. Wright, S.D., Burton, C., Hernandez, M., Hassing, H., Montenegro, J., Mundt, S., Patel, S., Card, D.J., Hermanowski-Vosatka, A., Bergstrom, J.D., Sparrow, C.P., Detmers, P.A., Chao, Y.S., Infectious agents are not necessary for murine atherogenesis. J. Exp. Med. 191 (2000), 1437–1442.
72. Yongqing, T., Drentin, N., Duncan, R.C., Wijeyewickrema, L.C., Pike, R.N., Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions?. Biochim. Biophys. Acta 1824 (2012), 253–262.
73. Yuen, J., Pluthero, F.G., Douda, D.N., Riedl, M., Cherry, A., Ulanova, M., Kahr, W.H., Palaniyar, N., Licht, C., NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways. Front. Immunol., 7, 2016, 137.
74. Zimmer, S., Grebe, A., Bakke, S.S., Bode, N., Halvorsen, B., Ulas, T., Skjelland, M., De Nardo, D., Labzin, L.I., Kerksiek, A., Hempel, C., Heneka, M.T., Hawxhurst, V., Fitzgerald, M.L., Trebicka, J., Bjorkhem, I., Gustafsson, J.A., Westerterp, M., Tall, A.R., Wright, S.D., Espevik, T., Schultze, J.L., Nickenig, G., Lutjohann, D., Latz, E., Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci. Transl. Med., 8, 2016 333ra350.